The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Phio’s presentation and live Q&A will take place on Thursday May 28, 2026, at 12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. REGISTER HERE: ...

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an ...

The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...

Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited success ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.